Pharmasynth is a leading brand in the field of molecular imaging, specializing in supplying precursors and standards for PET and SPECT imaging studies. Established in 2004, Pharmasynth aims to meet the growing demand for certified molecules used in PET and SPECT imaging, which have proven to be highly effective in detecting diseases in early stages and evaluating treatment effects. With expertise in molecule synthesis for brain studies, Pharmasynth is fast becoming a trusted partner in oncology and other therapeutic areas.

What sets us apart is the exceptional quality of our products, coupled with personalized assistance and reliability that we offer to our clients. We are devoted to working with precision and adhering to GMP guidelines to ensure the highest quality necessary for clinical use. Located in Tartu Science Park, Estonia, our production facilities benefit from the close proximity to Tartu University, allowing us to form intellectual partnerships and access specialized human resources.

This enables us to deliver high-quality chemistry in our state-of-the-art labs. Join us on our mission to drive advancements in medical diagnostics and improve patient outcomes